Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study.

Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C, Smit E, Weber J, Zuckerman M; UK Group on Transmitted HIV Drug Resistance.

BMJ. 2005 Dec 10;331(7529):1368. Epub 2005 Nov 18.

PMID:
16299012
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution.

Wirden M, Malet I, Derache A, Marcelin AG, Roquebert B, Simon A, Kirstetter M, Joubert LM, Katlama C, Calvez V.

AIDS. 2005 Mar 24;19(6):630-2.

PMID:
15802984
[PubMed - indexed for MEDLINE]
3.

Non-disclosure of previously known HIV seropositivity in patients "newly" diagnosed with HIV infection.

Natha M, Newell A, Pakianathan M.

Sex Transm Infect. 2005 Apr;81(2):182-3. No abstract available.

PMID:
15800104
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients.

Campo RE, Lalanne R, Tanner TJ, Jayaweera DT, Rodriguez AE, Fontaine L, Kolber MA.

AIDS. 2005 Mar 4;19(4):447-9. No abstract available.

PMID:
15750401
[PubMed - indexed for MEDLINE]
5.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Jan 28;19(2):153-62. No abstract available. Corrected and republished in: AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15668540
[PubMed - indexed for MEDLINE]
6.

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.

Røge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, Pedersen C, Mathiesen LR, Lundgren JD, Gerstoft J.

HIV Med. 2004 Sep;5(5):344-51.

PMID:
15369509
[PubMed - indexed for MEDLINE]
7.

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen.

Friend J, Parkin N, Liegler T, Martin JN, Deeks SG.

AIDS. 2004 Sep 24;18(14):1965-6. No abstract available.

PMID:
15353986
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group.

JAMA. 2004 Jul 14;292(2):191-201.

PMID:
15249568
[PubMed - indexed for MEDLINE]
9.

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks.

MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W.

AIDS. 2004 Mar 5;18(4):651-5.

PMID:
15090770
[PubMed - indexed for MEDLINE]
10.

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.

Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, Ghinelli F, Bertoli A, d'Arminio Monforte A, Perno CF, Moroni M, Balotta C.

AIDS. 2004 Jan 23;18(2):227-35.

PMID:
15075540
[PubMed - indexed for MEDLINE]
11.

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M.

J Infect Dis. 2004 Mar 1;189(5):837-46. Epub 2004 Feb 10.

PMID:
14976601
[PubMed - indexed for MEDLINE]
Free Article
12.

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E.

J Infect Dis. 2004 Jan 1;189(1):51-60. Epub 2003 Dec 31.

PMID:
14702153
[PubMed - indexed for MEDLINE]
Free Article
13.

Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.

Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team.

J Infect Dis. 2003 Aug 15;188(4):537-40. Epub 2003 Jul 24.

PMID:
12898440
[PubMed - indexed for MEDLINE]
Free Article
14.

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.

García-Lerma JG, MacInnes H, Bennett D, Reid P, Nidtha S, Weinstock H, Kaplan JE, Heneine W.

J Virol. 2003 May;77(10):5685-93.

PMID:
12719561
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E.

Antivir Ther. 2002 Sep;7(3):165-74.

PMID:
12487383
[PubMed - indexed for MEDLINE]
16.

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.

White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK.

Antimicrob Agents Chemother. 2002 Nov;46(11):3437-46.

PMID:
12384348
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.

Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M; CNA3002 International Study Team.

AIDS. 2002 Aug 16;16(12):1686-9.

PMID:
12172093
[PubMed - indexed for MEDLINE]
18.

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.

Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA.

J Virol. 2001 Aug;75(16):7462-9.

PMID:
11462018
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.

Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T.

Hepatology. 1999 Nov;30(5):1302-6.

PMID:
10534354
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk